Hijacking a death switch in pancreatic and lung cancer cells to develop a novel therapy

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/2002707

Funding Status
Status not available

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Pancreatic (PC) and lung (LC) cancer have a high mortality rate and poor response to current treatments. We have identified a protein whose inhibition in both PC and LC cells sensitises them to a cancer-cell specific therapy called TRAIL and switches signals that normally promote tumour growth into tumour death signals. This project aims to develop a novel therapeutic that inhibits our target and delivers TRAIL to PC and LC tumours, and could potentially improve survival for PC and LC patients.

Funded Activity Details

Start Date: 01-01-2020

End Date: End date not available

Funding Scheme: Ideas Grants

Funding Amount: $738,947.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cancer therapy | microtubules | nanotechnology | pancreatic cancer

Related Links